ImmunityBio, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ImmunityBio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q2 2024.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $9.64M, a 12.9% decline year-over-year.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $45.1M, a 7.65% increase year-over-year.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.2M, a 22.4% increase from 2022.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $40.2M, a 29.7% decline from 2021.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $57.2M, a 2515% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $45.1M $9.64M -$1.42M -12.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $46.6M $8.27M -$2.61M -24% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $49.2M $12.8M +$3.42M +36.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $45.7M $14.4M +$3.82M +35.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $41.9M $11.1M +$887K +8.72% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $41M $10.9M +$854K +8.52% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $40.2M $9.35M -$830K -8.15% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $41M $10.6M -$3.21M -23.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $44.2M $10.2M -$7.69M -43% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $51.9M $10M -$5.27M -34.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $57.2M $10.2M +$9.51M +1417% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-19
Q3 2021 $47.7M $13.8M +$13.1M +1838% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $34.5M $17.9M +$17.5M +5448% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $17M $15.3M +$14.8M +3087% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $2.19M $671K -$600K -47.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $2.79M $714K +$437K +158% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $2.35M $322K -$200K -38.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $2.55M $480K -$871K -64.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $3.42M $1.27M -$136K -9.67% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $3.56M $277K -$3.69M -93% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $7.25M $522K -$8.41M -94.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $15.7M $1.35M -$7.72M -85.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $23.4M $1.41M -$7.48M -84.2% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-04
Q3 2018 $30.9M $3.97M -$4.75M -54.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $35.6M $8.93M -$447K -4.77% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $36.1M $9.07M -$945K -9.43% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $37M $8.88M -$2.38M -21.1% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-25
Q3 2017 $39.4M $8.71M -$9.96M -53.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $49.3M $9.38M -$14M -59.8% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06
Q1 2017 $63.3M $10M -$10.5M -51.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
Q4 2016 $73.9M $11.3M -$10.1M -47.3% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-13
Q3 2016 $84M $18.7M -$20.3M -52.1% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $104M $23.4M -$103M -81.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 $207M $20.6M -$3.96M -16.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q4 2015 $211M $21.4M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-12
Q3 2015 $39M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $126M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 $24.5M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.